Based on the provided data, the sales of cardiac glycosides in Germany are forecasted to remain stable from 2024 through 2028, with a per capita value of 0.2 US dollars. By evaluating the values from 2024 to 2028, there is no year-on-year variation, implying a consistent trend without any growth or decline. As we are currently in 2024, the data does not include the actual figures for 2023, but it is crucial for comparative analysis.

Future trends to watch for include:

Potential advances in alternative heart disease treatments which may impact sales.
Regulatory changes affecting the pharmaceutical industry in Germany.
Demographic shifts, such as the aging population, which might influence the demand for cardiac glycosides.